Skip to main content

Candidiasis, Esophageal

2
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
2 programs
1
CaspofunginPhase 21 trial
L-743,872N/A1 trial
Active Trials
NCT00005921Completed18
NCT01165320Completed20Est. Sep 2013
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
CaspofunginPhase 2
L-743,872N/A
Bristol Myers Squibb
1 program
Amphotericin BN/A1 trial
Active Trials
NCT00002041Completed
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
L-743,872N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDCaspofungin

Clinical Trials (3)

Total enrollment: 38 patients across 3 trials

NCT01165320MSDCaspofungin

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Start: Jul 2010Est. completion: Sep 201320 patients
Phase 2Completed
NCT00005921MSDL-743,872

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

18 patients
N/ACompleted
NCT00002041Bristol Myers SquibbAmphotericin B

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.